When a Warning Advertises: The Boomerang Effect in Anti-Drug Campaigns and the Case of Concentrated 7-Hydroxymitragynine

Public service announcements and prohibition announcements share an assumption: that naming a danger reduces it. This commentary reviews evidence from health communication, prevention science and drug policy showing that the assumption fails under identifiable conditions (psychological reactance, null and iatrogenic campaign evaluations including DARE and the US National Youth Anti-Drug Media Campaign, and contrasting tobacco campaigns), states the counterevidence at full strength, and applies the record to the 2025 United States federal response to concentrated 7-hydroxymitragynine (7-OH). It includes a first-person lived-experience section on the United Kingdom mephedrone episode of 2009-2010, in which news coverage functioned in part as advertising, and argues for campaign design that warns without advertising, plus disease framing of addiction without a permanent addict identity. The author trained in family medicine and is not currently licensed to practise medicine; the article is scholarly commentary on communication and policy and contains no clinical or medication recommendations.